respiratory

News

FDA rejects Sunovion's nebulised COPD drug

The US regulator has rejected Sunovion’s nebulised therapy for chronic obstructive pulmonary disease (COPD), leaving the company struggling to stay ahead of rivals.

News

European regulators back Chiesi COPD triple therapy

Chiesi takes on Seretide and other lung drugs with Trimbow.

News

GSK gets short term boost as second US Advair generic reject...

FDA rejects Hikma drug, regulator has "major" issue with Mylan's rival.

News

GSK’s Relvar Ellipta comes out on top in real world study

Encouraging results will support growth of its next generation respiratory treatment

News

AZ hopes to boost respiratory pipeline with Pieris deal

AstraZeneca is hoping to boost its respiratory pipeline in a deal potentially worth more than $2 billion with US biotech Pieris Pharmaceuticals.

News

GSK to search for blockbusters under new CEO Walmsley

Big projects are priority as threat from generic Advair looms.

FDA rejects Sunovion's nebulised COPD drug

European regulators back Chiesi COPD triple therapy

GSK gets short term boost as second US Advair generic reject...

GSK’s Relvar Ellipta comes out on top in real world study

AZ hopes to boost respiratory pipeline with Pieris deal

GSK to search for blockbusters under new CEO Walmsley

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

respiratory

Editor's Picks